41 completed, 6 terminated, 2 unknown, 2 withdrawn. 51 Phase 1, 19 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 51 | Completed 41, Terminated 6, Unknown 2, Withdrawn 2 |
| Phase 2 | 19 | Completed 12, Terminated 5, Unknown 2 |
Follow Ribavirin: new trials by email Literature Review of Ribavirin trials Research Report on Ribavirin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHF Favipiravir, Ribavirin - CCHF | Phase 1 / Phase 2 | Unknown | Liverpool School of Tropical Medicine | 24 | 2023-07-12 | 2023-10-05 |
| Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19_#2 50 mg/mL Virazole, 100 mg/mL Virazole - COVID19 | Phase 1 | Withdrawn | Bausch Health Americas, Inc. | 2021-05-01 | 2025-09-16 | |
| Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19 50 mg/mL Virazole, 100 mg/mL Virazole - COVID19 | Phase 1 | Completed | Bausch Health Americas, Inc. | 51 | 2021-02-10 | 2021-08-26 |
| The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection P1101 + Ribavirin - Hepatitis C, Chronic | Phase 1 | Completed | PharmaEssentia | 17 | 2020-11-26 | 2022-08-30 |
| Bioequivalence Study of Ribavirin in Healthy Adult Subjects Under Fed Condition Ribavirin 400 mg film coated tablet (1*400mg), Copegus® 200 mg film coated tablet (2*200mg) - Healthy Subjects | Phase 1 | Completed | Future University in Egypt | 36 | 2020-10-11 | 2022-09-08 |
| A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia Brequinar/Brequinar + Ribavirin - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Clear Creek Bio, Inc. | 17 | 2018-12-20 | 2022-08-08 |
| Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4 OBV/PTV/r) ± ribavirin (RBV) - Hepatitis C Virus Infection | Phase 1 / Phase 2 | Completed | Beni-Suef University | 100 | 2017-01-05 | 2020-05-12 |
| Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection Sofosbuvir, Ribavirin, Ledipasvir/Sofosbuvir - HIV-1 Infection, Hepatitis | Phase 1 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 44 | 2014-05-30 | 2018-04-27 |
| Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C Chlorcyclizine HCl, Ribavirin - Chronic Hepatitis C | Phase 1 / Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 24 | 2014-03-20 | 2020-06-09 |
| Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C Ribavirin, Hydroxychloroquine - Hepatitis C | Phase 1 / Phase 2 | Terminated | BioLineRx, Ltd. | 4 | 2013-04-01 | 2014-08-28 |
| An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus Telaprevir, Peginterferon alfa-2b, Ribavirin - Hepatitis C | Phase 1 / Phase 2 | Terminated | Vertex Pharmaceuticals Incorporated | 42 | 2013-01-01 | 2016-07-20 |
| Viral Kinetics in HCV Clearance in Subjects With Hemophilia PegInterferon, Ribavirin, Telaprevir - Chronic Hepatitis C, Hemophilia | Phase 1 | Completed | Kenneth Sherman | 5 | 2012-12-01 | 2015-04-06 |
| Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC) Afatinib, Ribavirin, and weekly carboplatin/paclitaxel - Head and Neck Cancer, Squamous Cell Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 10 | 2012-11-01 | 2017-10-25 |
| Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048) Vaniprevir 600 mg, Peg-IFN alfa-2b, Ribavirin - Chronic Hepatitis C | Phase 1 | Completed | Merck Sharp & Dohme LLC | 31 | 2012-10-30 | 2022-08-26 |
| Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants ACH-0143102, Ribavirin - Chronic Hepatitis C Infection | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 8 | 2012-09-01 | 2023-08-29 |
| A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets ribavirin [Copegus] - Healthy Volunteer | Phase 1 | Completed | Hoffmann-La Roche | 40 | 2012-09-01 | 2016-11-02 |
| Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022) Peg-Interferon, Liver Samples from FNA, Liver Samples from CNB - Chronic Hepatitis C | Phase 1 | Withdrawn | Merck Sharp & Dohme LLC | 2012-05-01 | 2015-10-14 | |
| Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients midazolam, BI 201335, tenofovir - Hepatitis C, Chronic | Phase 1 | Completed | Boehringer Ingelheim | 72 | 2012-04-01 | 2016-06-10 |
| Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients. SOF, EFV/FTC/TDF, EFV - Hepatitis C, HIV | Phase 1 / Phase 2 | Completed | Gilead Sciences | 52 | 2012-03-01 | 2014-10-01 |
| Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects 200 mg INX-08189 Fasted, Placebo QD Fasted, 100 mg INX-08189 QD - Hepatitis C | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 50 | 2011-09-01 | 2016-06-27 |
Showing 20 of 51. Sign in to see all of them.
Hepatitis C (17) · Hepatitis C, Chronic (14) · HIV Infections (9) · AIDS-Related Complex (4) · Acquired Immunodeficiency Syndrome (4) · COVID-19 (2) · Hepatitis (2) · Leukemia, Myeloid, Acute (2) · Breast Neoplasms (1) · Bronchiolitis Obliterans Syndrome (1) · Coinfection (1) · Fibrosis (1) · Head and Neck Neoplasms (1) · Hemophilia A (1) · Hepatic Insufficiency (1)
National Institute of Allergy and Infectious Diseases (NIAID) (8) · Hoffmann-La Roche (3) · Jewish General Hospital (3) · Bausch Health Americas, Inc. (2) · Boehringer Ingelheim (2) · Bristol-Myers Squibb (2) · Merck Sharp & Dohme LLC (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Sandoz (2) · Teva Pharmaceuticals USA (2) · Vertex Pharmaceuticals Incorporated (2) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1) · Alexion Pharmaceuticals, Inc. (1) · Beni-Suef University (1) · BioLineRx, Ltd. (1)
United States (27) · Puerto Rico (6) · Canada (5) · France (2) · Germany (2) · Mexico (2) · Poland (2) · United Kingdom (2) · Argentina (1) · Belgium (1) · Egypt (1) · Greece (1) · Italy (1) · Japan (1) · New Zealand (1)
Anya Loncaric (2) · Crumpacker C (2) · Katherine Borden, PhD (2) · Piyush Patel, M.D. (2) · So Ran Hong, M.D. (2) · Adriana Andrade, MD (1) · Alan Winston, MB BH (1) · Anuj Gaggar, MD/PhD (1) · Christopher Koh, M.D. (1) · David Pfister, MD (1) · Fumitaka Suzuki, MD (1) · Hala Masoud, PhD (1)
PMID 21354234, PMID 21406434, PMID 23190247, PMID 23264438, PMID 23396509, PMID 23872824, PMID 23982366, PMID 24295986, PMID 24982088, PMID 24983321, PMID 25425688, PMID 25622055, PMID 25733369, PMID 26733671, PMID 26869690, PMID 28329053, PMID 29638206, PMID 31220220, PMID 31868916
2009 (2), 2008 (1), R01AI049141 (1), R34HL109334 (1), U01AI048224 (1), UM1AI068636 (1)